Join
Live feed
·
PRReleasevia Quantisnow
Nexalin Technology Inc. logo

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study

ByQuantisnow·Wall Street's wire, on your screen.
NXL· Nexalin Technology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NXL (Nexalin Technology Inc.) and more on Quantisnow.